The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. The index has shown a price gain of 15.90% this year. Over the last six months, there has been a weaker performance of 54.70%. The price of ITCI fallen by 28.14% during the last 30 days period. For the last 5-days stocks have improved 20.97%.
Intra-Cellular Therapies Inc’s stock has had a calm market performance. The 1-year high for the company’s stock was $76.11 on 04/16/24, and the lowest price during the same period was recorded at $45.50 on 10/30/23.
52-week price history of ITCI Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Intra-Cellular Therapies Inc’s current trading price is 9.07% away from its 52-week high, while its distance from the 52-week low is 82.44%. The stock’s price range for this period has been between $45.50 and $76.11. The Healthcare sector company’s shares saw a trading volume of about 3.95 million for the day, which was higher than the average daily volume of 0.75 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Intra-Cellular Therapies Inc (ITCI) has experienced a quarterly rise of 23.03% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 8.04B and boasts a workforce of 610 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 67.43, with a change in price of +22.22. Similarly, Intra-Cellular Therapies Inc recorded 814,665 in trading volume during the last 100 days, posting a change of +37.94%.
ITCI’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for ITCI stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.
ITCI Stock Stochastic Average
As of today, the raw stochastic average of Intra-Cellular Therapies Inc over the last 50 days is at 94.39%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 94.05%. Further, the company’s Stochastic %K and %D values for the last 20 days were 46.94% and 46.31%, respectively.
